Recruitment status
- Recruiting16
- Active, not recruiting7
- Completed5
- Not yet recruiting4
- Unknown status3
- Enrolling by invitation1
- Suspended1
- Withdrawn1
Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Canada trial landscape
Psilocybin Clinical Trials in Canada
Review psilocybin studies with at least one registry-listed site in Canada and move directly from country-level discovery to the authoritative trial record.
Registry status is not a guarantee of local availability, eligibility, safety, or efficacy. Confirm every participation decision in the authoritative ClinicalTrials.gov record.
38matching trials
16currently recruiting
178registry-listed sites
Registry facts checkedAug 10, 2026 01:26 UTC
Live registry synthesis
Status, geography, and study phase
This collection uses structured site-country facts rather than investigator or sponsor addresses. Registry status does not guarantee that a particular Canadian site is currently enrolling.
Leading countries
- Canada38
- United States2
- Czechia2
- Denmark2
- Germany2
- Ireland2
- Netherlands2
- Spain2
Trial phases
- Phase 228
- Phase 18
- Phase 33
- Not applicable1
Server-rendered source index
38 matching registry records
Every factual summary is crawlable without JavaScript. Use the direct registry link for current eligibility, contacts, and site availability.
Active, not recruitingNCT06731621
Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand Mechanism
Centre for Addiction and Mental Health
- Conditions
- Treatment Resistant Depression · Autism Spectrum Disorder
- Phase
- Phase 1
- Enrollment
- 20 estimated
- Locations
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Registry updated
- 2026-08-06
Enrolling by invitationNCT07737990
Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression
Joshua Rosenblat
- Conditions
- Treatment-resistant Depression (TRD)
- Phase
- Not applicable
- Enrollment
- 65 estimated
- Locations
- Toronto Western Hospital, Toronto, Ontario, Canada
- Registry updated
- 2026-07-30
RecruitingNCT06512220
Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)
Centre for Addiction and Mental Health
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 12 estimated
- Locations
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Registry updated
- 2026-07-30
RecruitingNCT06518720
Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial
Centre for Addiction and Mental Health
- Conditions
- Treatment Resistant Depression · Chronic Pain
- Phase
- Phase 2
- Enrollment
- 16 estimated
- Locations
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Registry updated
- 2026-07-30
RecruitingNCT07211438
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial
Centre for Addiction and Mental Health
- Conditions
- Treatment-Resistant Depression
- Phase
- Phase 2
- Enrollment
- 40 estimated
- Locations
- Toronto Western Hospital (University Health Network), Toronto, Ontario, Canada · Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Registry updated
- 2026-07-30
Active, not recruitingNCT06299319
Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical Trial
Centre for Addiction and Mental Health
- Conditions
- Obsessive-Compulsive Disorder
- Phase
- Phase 1
- Enrollment
- 10 estimated
- Locations
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Registry updated
- 2026-07-28
CompletedNCT07710027
A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of Psilocybin
Diamond Therapeutics Inc.
- Conditions
- Healthy Controls
- Phase
- Phase 1
- Enrollment
- 56 actual
- Locations
- BioPharma Services Inc., Toronto, Ontario, Canada
- Registry updated
- 2026-07-17
RecruitingNCT07063862
PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial
Bruyère Health Research Institute.
- Conditions
- Psychological Distress
- Phase
- Phase 3
- Enrollment
- 120 estimated
- Locations
- William Osler Health System, Brampton, Ontario, Canada · Providence Care Hospital, Kingston, Ontario, Canada · St. Joseph's Healthcare, London, Ontario, Canada · +4 more
- Registry updated
- 2026-07-10
Active, not recruitingNCT04754061
PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical Trial
Ottawa Hospital Research Institute
- Conditions
- Depression, Anxiety · Distress, Emotional
- Phase
- Phase 1 · Phase 2
- Enrollment
- 20 estimated
- Locations
- The Ottawa Hospital, Ottawa, Ontario, Canada · Bruyere Continuing Care, Ottawa, Ontario, Canada
- Registry updated
- 2026-07-10
Active, not recruitingNCT06341426
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)
University Health Network, Toronto
- Conditions
- Major Depressive Disorder · Depression · Treatment-Resistant Depression · Mood Disorders
- Phase
- Phase 2
- Enrollment
- 92 estimated
- Locations
- Toronto Western Hospital, Toronto, Ontario, Canada · Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada
- Registry updated
- 2026-07-09
RecruitingNCT06386003
Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial
Unity Health Toronto
- Conditions
- Post Traumatic Stress Disorder · PTSD · Chronic PTSD
- Phase
- Phase 2
- Enrollment
- 15 estimated
- Locations
- St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
- Registry updated
- 2026-06-26
RecruitingNCT07048743
Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial
University Health Network, Toronto
- Conditions
- Caregiver Distress
- Phase
- Phase 2
- Enrollment
- 15 estimated
- Locations
- Toronto General Hospital, Toronto, Ontario, Canada
- Registry updated
- 2026-06-23
Active, not recruitingNCT06416085
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label Trial
University Health Network, Toronto
- Conditions
- Advanced Cancer · Stage IV Solid Tumor Cancer · Stage IV Sarcoma of Bone · Stage IV Lymphoma
- Phase
- Phase 2
- Enrollment
- 15 estimated
- Locations
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- Registry updated
- 2026-06-22
RecruitingNCT06768944
The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults
University of Calgary
- Conditions
- Investigating the Importance of the Subjective Psychedelic Experience
- Phase
- Phase 2
- Enrollment
- 128 estimated
- Locations
- University of Calgary, Calgary, Alberta, Canada
- Registry updated
- 2026-06-02
Not yet recruitingNCT06885996
Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence
University of Calgary
- Conditions
- Post Traumatic Stress Disorder PTSD · Intimate Partner Violence (IPV)
- Phase
- Phase 2
- Enrollment
- 76 estimated
- Locations
- University of Calgary, Calgary, Alberta, Canada · The University of British Columbia - Okanagan Campus, Kelowna, British Columbia, Canada
- Registry updated
- 2026-05-14
CompletedNCT05710237
Does Psilocybin Require Psychedelic Effects to Treat Depression? A 4-Week, Double-Blind, Proof-of-Concept Randomized Controlled Trial
Centre for Addiction and Mental Health
- Conditions
- Treatment-resistant Depression
- Phase
- Phase 2
- Enrollment
- 41 actual
- Locations
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Registry updated
- 2026-05-07
Not yet recruitingNCT06943573
Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled Trial
Lakshmi N Yatham
- Conditions
- Bipolar II Depression
- Phase
- Phase 3
- Enrollment
- 90 estimated
- Locations
- Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia, Canada · Department of Psychiatry, University of Ottawa, The Ottawa Hospital, Ottawa, Ontario, Canada · Department of Psychiatry, University of Toronto, University Health Network,, Toronto, Ontario, Canada
- Registry updated
- 2026-05-01
Not yet recruitingNCT07373535
Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted Psychotherapy
Kyle Greenway
- Conditions
- Treatment-Resistant Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 16 estimated
- Locations
- Jewish General Hospital, Montreal, Quebec, Canada
- Registry updated
- 2026-04-22
RecruitingNCT06072898
Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression
Sunnybrook Health Sciences Centre
- Conditions
- Depressive Disorder · Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 50 estimated
- Locations
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Registry updated
- 2026-03-30
RecruitingNCT06818994
Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study
Gustavo Vazquez
- Conditions
- Demoralization · Safety
- Phase
- Phase 1
- Enrollment
- 15 estimated
- Locations
- Queen's University, Kingston, Ontario, Canada
- Registry updated
- 2026-03-18
Active, not recruitingNCT06041152
Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive Impairment
Centre for Addiction and Mental Health
- Conditions
- Amnestic Mild Cognitive Impairment
- Phase
- Phase 2
- Enrollment
- 10 actual
- Locations
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Registry updated
- 2026-02-25
Not yet recruitingNCT07405606
Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical Trial
Centre for Addiction and Mental Health
- Conditions
- Major Depressive Disorder (MDD) · Alcohol Use Disorder (AUD)
- Phase
- Phase 2
- Enrollment
- 30 estimated
- Locations
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Registry updated
- 2026-02-12
Active, not recruitingNCT05711940
A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression
COMPASS Pathways
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 3
- Enrollment
- 572 actual
- Locations
- Lighthouse Psychiatry Scottsdale, Gilbert, Arizona, United States · Clinical Innovations, Inc., Bellflower, California, United States · M3 Wake Research, Encino, California, United States · +113 more
- Registry updated
- 2026-01-12
RecruitingNCT06615908
A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility Trial
University of Calgary
- Conditions
- Persisting Symptoms After Concussion
- Phase
- Phase 1
- Enrollment
- 40 estimated
- Locations
- University of Calgary, Calgary, Alberta, Canada
- Registry updated
- 2025-12-30
CompletedNCT05259943
Microdosing Psychedelics to Improve Mood
Rotem Petranker
- Conditions
- Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 39 actual
- Locations
- Psych Research, Toronto, Ontario, Canada
- Registry updated
- 2025-12-30
RecruitingNCT05585229
Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility Study
University of British Columbia
- Conditions
- Opioid Dependence · Chronic Pain
- Phase
- Phase 2
- Enrollment
- 10 estimated
- Locations
- University of British Columbia - Okanagan Campus, Kelowna, British Columbia, Canada
- Registry updated
- 2025-12-04
RecruitingNCT06969170
A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder
Queen's University
- Conditions
- Generalized Anxiety Disorder (GAD)
- Phase
- Phase 2
- Enrollment
- 50 estimated
- Locations
- Kingston General Health Research Institute, Kingston, Ontario, Canada
- Registry updated
- 2025-05-13
RecruitingNCT06731335
Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN
Unity Health Toronto
- Conditions
- Chronic Neuropathic Pain · Pain Management
- Phase
- Phase 2
- Enrollment
- 30 estimated
- Locations
- St. Michael's Hospital. Unity Health Toronto, Toronto, Ontario, Canada
- Registry updated
- 2025-03-30
RecruitingNCT06225232
An 8-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study
McMaster University
- Conditions
- Cannabis Use Disorder, Moderate · Cannabis Use Disorder, Severe
- Phase
- Phase 2
- Enrollment
- 16 estimated
- Locations
- MacAnxiety Research Centre, Hamilton, Ontario, Canada
- Registry updated
- 2025-03-19
RecruitingNCT06506019
Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study
University Health Network, Toronto
- Conditions
- Bipolar Depression
- Phase
- Phase 1
- Enrollment
- 30 estimated
- Locations
- Toronto Western Hospital - University Health Network, Toronto, Ontario, Canada
- Registry updated
- 2024-10-18
Unknown statusNCT05646303
A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)
Clairvoyant Therapeutics
- Conditions
- Alcohol Use Disorder
- Phase
- Phase 2
- Enrollment
- 128 estimated
- Locations
- Sabi Mind, Calgary, Alberta, Canada · Okanagan Clinical Trials, Kelowna, British Columbia, Canada · Centre for Neurology Studies, Surrey, British Columbia, Canada · +9 more
- Registry updated
- 2024-08-15
Unknown statusNCT06471959
Assessing the Feasibility of a Custom Psychedelic-assisted Group Program on Mental and Physical Health in First Responders
Empower Research Inc
- Conditions
- Psilocybin · Psychotherapy, Group
- Phase
- Phase 1 · Phase 2
- Enrollment
- 32 estimated
- Locations
- Centre for Neurology Studies, Surrey, British Columbia, Canada
- Registry updated
- 2024-06-24
SuspendedNCT05832255
An Open-Label Investigation of the Effects of Sub-Perceptual Repeat Dosing of Psilocybin on the Behavioural and Cognitive Symptoms of Fragile X Syndrome in Adult Patients
Nova Mentis Life Science Corp
- Conditions
- Fragile X Syndrome · Behavior · Cognitive Dysfunction
- Phase
- Phase 2
- Enrollment
- 10 estimated
- Locations
- KGK Science Inc., London, Ontario, Canada
- Registry updated
- 2024-05-08
RecruitingNCT05995769
Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical Trial
University of Calgary
- Conditions
- Alcohol Use Disorder · Alcoholism
- Phase
- Phase 2
- Enrollment
- 128 estimated
- Locations
- University of Calgary, Calgary, Alberta, Canada
- Registry updated
- 2024-05-07
CompletedNCT05029466
The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility Study
Brain and Cognition Discovery Foundation
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 30 actual
- Locations
- Canadian Rapid Treatment Centre of Excellence (CRTCE), Mississauga, Ontario, Canada
- Registry updated
- 2023-07-27
WithdrawnNCT05594667
Evaluating the Effect of Length of Time on Selective Serotonin Reuptake Inhibitors (SSRIs) on the Response to Psilocybin-assisted Therapy in Individuals With Mild-moderate Major Depressive Disorder (MDD)
Cybin Therapeutics Inc.
- Conditions
- Depression · Major Depressive Disorder · Mild Depression · Moderate Depression
- Phase
- Phase 2
- Enrollment
- 0 actual
- Locations
- Centre for Neurology Studies x Upstream, Abbotsford British Columbia, British Columbia, Canada
- Registry updated
- 2023-07-06
Unknown statusNCT05243329
Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder
Halucenex Life Sciences Inc.
- Conditions
- Treatment Resistant Disorders · Post Traumatic Stress Disorder
- Phase
- Phase 2
- Enrollment
- 20 estimated
- Locations
- Halucenex Life Sciences Inc., Windsor, Nova Scotia, Canada
- Registry updated
- 2023-06-29
CompletedNCT03775200
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
COMPASS Pathways
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 233 actual
- Locations
- Kadima Neuropsychiatry Institute, La Jolla, California, United States · Altman Clinical and Translational Research Institute, University of California, San Diego, California, United States · Stanford Department of Psychiatry, Stanford, California, United States · +22 more
- Registry updated
- 2023-04-24
Related research views
Continue exploring clinical trials
Move between curated condition, country, phase, and recruiting views without losing direct source provenance.
Recruitment
Conditions
Countries
Phases
Method and accountability
How this collection is maintained
Automatic refresh: counts, facets, records, and the map update from the tracker after scheduled ClinicalTrials.gov refreshes. The registry remains authoritative.
Rights-safe scope: the page exposes allowlisted factual metadata. Registry descriptions, contacts, raw payloads, and source-derived keywords are not redistributed.
Editorial review: collection definitions, limitations, corrections, and authorship are documented in the editorial and methodology policy.